Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04284280 · ClinicalTrials.gov registry record · NA

Early Routine vs. Selective Human Milk Fortification in Extremely Preterm Infants

A NA study of Necrotizing Enterocolitis and Poor Growth in Extremely Preterm Infants, sponsored by Crouse Hospital.

Recruiting
Registry status
NA
Development phase
200
Enrollment target
1
Study location

NCT04284280 is a NA study of Necrotizing Enterocolitis and Poor Growth in Extremely Preterm Infants that is actively recruiting participants, run by Crouse Hospital. The registered enrollment target is 200 participants, below the 299-participant average among 14 other Necrotizing Enterocolitis trials with a reported enrollment target (33% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04284280, a NA study of Necrotizing Enterocolitis and Poor Growth in Extremely Preterm Infants, is actively recruiting participants, sponsored by Crouse Hospital.

RECRUITING
Registry status
NA
Development phase
200 participants
Enrollment target
1
Study location

Study Summary

The aim of the project is to study the effects of fortification (using a Human Milk Donor Fortifier) of an exclusive preterm human milk diet on outcome of extremely preterm neonates, born at less or equal to 27 weeks.

Interventions

  • DIETARY_SUPPLEMENT Routine vs Selective use of Human Milk Donor Fortifier

Study Locations (1)

New York

  • Crouse Hospital - Syracuse

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2020-02-15
Est. Completion 2027-02-01
Phase NA

Sponsor

Crouse Hospital

2 total trials

What the Registry Record Tells You About NCT04284280

The ClinicalTrials.gov registry entry for NCT04284280 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 299-participant average among 14 other Necrotizing Enterocolitis trials with a reported enrollment target (33% lower). The listed sponsor is Crouse Hospital, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Necrotizing Enterocolitis appearing as the primary indexed condition, and to 1 intervention - of which Routine vs Selective use of Human Milk Donor Fortifier is the first listed.

NCT04284280 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT04284280 about?

NCT04284280 is a clinical study titled "Early Routine vs. Selective Human Milk Fortification in Extremely Preterm Infants". The aim of the project is to study the effects of fortification (using a Human Milk Donor Fortifier) of an exclusive preterm human milk diet on outcome of extremely preterm neonates, born at less or equal to 27 weeks.

What is the current status of trial NCT04284280?

This trial is currently recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2020-02-15. Estimated completion is 2027-02-01.

What conditions does trial NCT04284280 study?

This clinical trial studies the following conditions: Necrotizing Enterocolitis, Poor Growth in Extremely Preterm Infants.

What interventions are being tested in trial NCT04284280?

The interventions under investigation include: Routine vs Selective use of Human Milk Donor Fortifier (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT04284280?

This trial is sponsored by Crouse Hospital, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04284280 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Necrotizing Enterocolitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.